Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Correction: Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria

  • The PLOS ONE Staff
  • Article
  • Metrics
  • Comments
  • Media Coverage

There are errors in the formatting of Figure 3 and Table 4.

thumbnail
Figure 3. Common estimates where justified and indirect comparisons of all BID or QD dosing regimens of NOACs.

Results are expressed from the respective main dose results of the phase 3 trials [1]–[5] in the intent-to-treat analysis for efficacy (Stroke and systemic embolism, ischemic stroke) and in the safety analysis for intracranial hemorrhage. AP, apixaban; BID, twice-daily dosing; CE, common estimate; CI, confidence interval; DE, dabigatran etexilate; EDOX, edoxaban; HR, hazard ratio; QD, once-daily dosing; RIVA, rivaroxaban; SE, systemic embolism; W, warfarin; aIn the ROCKET-AF trial, only ischemic strokes, excluding unspecified strokes, are reported. Note: bold and italic font marks significantly superior results.

https://doi.org/10.1371/journal.pone.0099276.g003

thumbnail
Table 4. Analysis of results heterogeneity of NOACs vs warfarin.

https://doi.org/10.1371/journal.pone.0099276.t004

Please see the corrected Figure 3 here.

Please see the corrected Table 4 here.

Reference

  1. 1. Clemens A, Noack H, Brueckmann M, Lip GYH (2014) Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria. PLoS ONE 9(6): e99276